Clinical Trial Update: An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy [EARLY_Phase 1]

View source ↗

Summary

An exploratory early-phase clinical trial of an anti-CD19/BCMA CAR NK cell therapy for IgA nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• anti-CD19/BCMA CAR NK cell therapy

Snippet

Sponsor: Jieyang People's Hospital | Conditions: IgA Nephropathy (IgAN) | EARLY_Phase 1 | Status: WITHDRAWN